Loading...
NPI 1699782722 · Nashville, TN · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Aegis Sciences Corporation is a clinical medical laboratory provider located in Nashville, Tennessee. This profile covers 20 Medicare and 104 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Aegis Sciences Corporation |
| Address | 530 Great Circle Rd |
| City | Nashville |
| State | TN |
| ZIP | 37228 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 2, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $193.8M |
| Medicare | $34.5M |
AEGIS SCIENCES CORPORATION’s CPT/HCPCS mix identifies it as a high-volume reference toxicology and confirmatory drug-testing laboratory: its Medicare top codes are dominated by definitive drug panels G0482 ($16.7M, 48.4% of Medicare revenue), G0483 ($9M, 26.2%), and the presumptive screen 80307 ($4M, 11.7%), and Medicaid shows the same service line leadership with large volumes of definitive panels and targeted analyte tests. The presence of many 803xx and G048x codes in the top lists indicates the operation focuses on both instrumented presumptive screening and higher-complexity mass-spectrometry confirmation testing rather than routine clinical chemistry alone.
Revenue concentration on Medicare is highly concentrated: the three highest-revenue Medicare codes account for 86.3% of the provider’s total Medicare revenue, signaling that a small set of toxicology services drive nearly all Medicare receipts and that Medicare performance is therefore tightly linked to demand and reimbursement for those specific drug-testing codes. This concentration creates both operational leverage and payer-concentration exposure around confirmatory drug testing.
Medicaid revenue is also concentrated by a small set of tests: the three highest-revenue Medicaid codes (including G0482 $54.4M, G0481 $34.6M, and 80307 $34.4M) account for 66.1% of the provider’s total Medicaid revenue. Those Medicaid figures—particular the $54.4M for G0482—show the same completion/confirmation-focused service mix at scale within the state Medicaid program.
AEGIS’s payer mix is heavily skewed toward Medicaid in scale: lifetime Medicare revenue is $34.5M versus total Medicaid revenue of $193.8M, indicating Medicaid is the dominant source of billed revenue for this provider. This disparity implies the provider’s commercial and operational priorities are likely aligned to state-level program volume and contracts rather than Medicare as the primary revenue driver.
On competitive standing, AEGIS is a national leader in key Medicare toxicology codes: G0482 ranks #1 of 1618 providers nationally and is described as an extreme outlier (100th percentile), G0483 ranks #2 of 1063 providers (100th percentile; extreme outlier), and several other Medicare codes also sit at very high percentiles. Those national ranks indicate AEGIS operates at volumes far above typical peer labs for confirmatory drug testing on Medicare patients and should be considered a top-tier national player for these services.
Within Tennessee Medicaid, AEGIS is similarly dominant: multiple high-revenue Medicaid codes (G0482, G0481, G0483, G0480, 80307, 82542 and many specific 803xx analyte codes) are ranked #1 in-state and repeatedly characterized as extreme outlier or notably above typical state volume. This pattern supports the view that AEGIS is the leading in-state provider for both presumptive and definitive drug testing and captures sizable share of state Medicaid toxicology claims.
The provider offers a broad menu of targeted analytic tests in addition to bundled definitive panels, as evidenced by substantial Medicaid revenues for single-analyte and small-panel codes (examples include 80348 $843.6K, 80354 $698.2K, 80356 $709.4K, and numerous other 803xx entries ranked #1 in-state). That breadth—many high-volume, named-analyte CPTs alongside large-volume multi-class confirmatory panels—signals capability to support clinical, addiction-treatment, and monitoring workflows that require both screening and analyte-specific confirmation.
AEGIS has a long operational tenure: the NPI was enumerated on 2006-08-02 (~20 years ago), and the combination of longevity plus the extremely high claim counts and revenue concentrations across both Medicare and Medicaid suggests an established reference-laboratory infrastructure and sustained referrals for toxicology services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
20 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 86,020 | $190 | $16.7M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 37,540 | $240 | $9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 66,090 | $60 | $4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 21,480 | $150 | $3.3M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6,540 | $110 | $719.4K |
| 82542 | The lab analyst performs the technical lab test to evaluate the specimen for the presence or amount of a nondrug analyte by using column chromatography and possibly mass spectrometry. | 20,020 | $20 | $480.4K |
| 84228 | The lab analyst performs a test to evaluate the level of quinine in a patient specimen such as serum or plasma. | 20,010 | $10 | $220.1K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 390 | $10 | $3.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 130 | $10 | $1.3K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 80 | $20 | $1.2K |
Showing 1–10 of 20
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
20 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0482 | 1 | 80 | 70 | $190 | $249.9K |
| 82542 | 1 | 10 | 10,060 | $20 | $237.2K |
| 84228 | 1 | 10 | 20,010 | $10 | $227.7K |
| G0483 | 1 | 70 | 120 | $240 | $181.5K |
| G0481 | 1 | 60 | 80 | $150 | $73.2K |
| 80307 | 1 | 250 | 140 | $60 | $30.1K |
| G0480 | 1 | 70 | 80 | $110 | $29.1K |
| 86803 | 10 | 20 | 20 | $10 | $8.9K |
| 87389 | 4 | 10 | 110 | $20 | $8.2K |
| 80053 | 906 | 1,600 | 160 | $10 | $4.3K |
Showing 1–10 of 20
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
104 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,088,900 | $50 | $54.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 509,140 | $70 | $34.6M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,272,440 | $30 | $34.4M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 422,720 | $60 | $27.1M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 380,520 | $30 | $12.6M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 117,410 | $70 | $8.2M |
| 82542 | The lab analyst performs the technical lab test to evaluate the specimen for the presence or amount of a nondrug analyte by using column chromatography and possibly mass spectrometry. | 341,200 | $10 | $2M |
| 84228 | The lab analyst performs a test to evaluate the level of quinine in a patient specimen such as serum or plasma. | 330,930 | $10 | $1.7M |
| 80325 | The lab analyst measures the amount of or detects the presence of three or four amphetamines, a central nervous system stimulant in the patient specimen. | 134,510 | $10 | $941.5K |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 140,600 | $10 | $843.6K |
Showing 1–10 of 104
How this provider's Medicaid billing volume and revenue compare to other Tennessee providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Tennessee median
104 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 84228 | The lab analyst performs a test to evaluate the level of quinine in a patient specimen such as serum or plasma. | 1 | 10 | 330,930 | $1 | $1.6M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 60 | 430 | $50 | $1M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 60 | 840 | $60 | $705.4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 70 | 180 | $60 | $589.9K |
| 80344 | The lab analyst measures the amount of or detects the presence of seven or more antipsychotics, in a patient specimen. The antipsychotics that the analyst measures are not specified by other CPT®… | 1 | 10 | 47,940 | $10 | $548.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3 | 100 | 400 | $60 | $524.7K |
| 82542 | The lab analyst performs the technical lab test to evaluate the specimen for the presence or amount of a nondrug analyte by using column chromatography and possibly mass spectrometry. | 1 | 10 | 550 | $10 | $499K |
| 82415 | The lab analyst determines the drug level of chloramphenicol, a broad spectrum antibiotic, on a serum or plasma sample. Providers rarely order this test because they rarely prescribe the drug due to… | 1 | 10 | 49,370 | $10 | $326.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 240 | 840 | $20 | $259.2K |
| 80340 | The lab analyst measures the amount of or detects the presence of four to six antiepileptics in a patient specimen. The antiepileptics the provider is testing for are not specified in other CPT®… | 1 | 10 | 18,560 | $10 | $247.1K |
Showing 1–10 of 104
Other providers in the same ZIP code as Aegis Sciences Corporation, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.